Brief communication on the impact of β-blockers on outcomes in patients receiving cancer immunotherapy
AffiliationChristie NHS Foundation Trust
MetadataShow full item record
AbstractPreclinical studies show that β-adrenergic activation suppresses the immune system and reduces the effectiveness of cancer immunotherapy. As a result, there is considerable interest in using β-blockers (BBs), a cheap and safe class of medication, in combination with immunotherapy to improve outcomes in cancer. This study is a systematic review and meta-analysis of clinical studies. A comprehensive literature search was performed up to May 2022. Studies were included if they reported hazard ratios (HRs) of overall survival (OS), all-cause mortality or progression-free survival (PFS) associated with BBs in patients with solid organ cancer treated with immunotherapy. Study-specific HRs and 95% confidence intervals were pooled in random effects meta-analyses. Nine studies involving over 6350 patients with melanoma, lung, renal, urothelial, or other solid cancers treated with a range of immunotherapies met the inclusion criteria. Across all studies combined, there was no association between concomitant BB use and OS (HR 0.99, 0.83-1.18) or PFS (HR 0.97, 0.89-1.05). In subgroup analyses, BB use made no difference to OS or PFS in melanoma (OS HR 0.66, 0.33-1.34; PFS HR 0.81, 0.62-1.05) or to OS in lung cancer (OS HR 1.00, 0.49-2.07). In summary, this study found no evidence that BBs enhance immunotherapy effectiveness.
CitationKennedy OJ, Neary MT. Brief Communication on the Impact of β-blockers on Outcomes in Patients Receiving Cancer Immunotherapy. Journal of immunotherapy (Hagerstown, Md : 1997). 2022 Sep 1;45(7):303-6. PubMed PMID: 35947120. Epub 2022/08/11. eng.
JournalJournal of Immunotherapy
- Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
- Authors: Dammeijer F, Lievense LA, Veerman GD, Hoogsteden HC, Hegmans JP, Arends LR, Aerts JG
- Issue date: 2016 Sep 10
- An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
- Authors: Liu C, Guo H, Mao H, Tong J, Yang M, Yan X
- Issue date: 2022
- Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
- Authors: Park R, Lopes L, Saeed A
- Issue date: 2021 Jan
- Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis.
- Authors: Jin J, Yang L, Liu D, Li W
- Issue date: 2020 Jun 3
- Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
- Authors: Yang M, Wang Y, Yuan M, Tao M, Kong C, Li H, Tong J, Zhu H, Yan X
- Issue date: 2020 Nov